Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
Prior to joining Eyenovia, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, where he was responsible for the US and international commercialization, planning, and execution for Rhopressa for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals, Women First Healthcare, and Pfizer. Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.
“We are excited to welcome Michael to the Eyenovia team as our Vice President of Marketing,” Sean Ianchulev, MD, Eyenovia’s Chief Executive Officer and Chief Medical Officer, said in a company news release. “As Eyenovia advances its late stage pipeline, we believe Michael can help us further develop our marketing strategy and focus our commercial efforts. We believe his extensive experience leading the strategic direction for the commercialization of various products at Aerie, Allergan and Bayer can help us realize our vision to transform the ophthalmic space.”
“I believe Eyenovia’s micro-therapeutic approach and diverse late stage pipeline has the ability to offer the field of ophthalmology a novel and sophisticated way to treat patients with front and back of the eye conditions,” Mr. Rowe said. “With the potential to commercialize two new products for mydriasis and dry eye in the next 18 months, as well as initiate phase 3 trials in myopia and chronic angle-closure glaucoma by mid-2019, I look forward to working with the team on developing and executing a robust commercialization plan that can help lead Eyenovia’s success.”